PACIRA BIOSCIENCES INC (PCRX)
US6951271005 - Common Stock
PCRX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. PCRX has an excellent profitability rating, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on PCRX. These ratings would make PCRX suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year PCRX was profitable.
PCRX had a positive operating cash flow in the past year.
PCRX had positive earnings in 4 of the past 5 years.
PCRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.46%, PCRX belongs to the top of the industry, outperforming 86.60% of the companies in the same industry.
PCRX has a better Return On Equity (7.91%) than 87.11% of its industry peers.
PCRX's Return On Invested Capital of 4.27% is amongst the best of the industry. PCRX outperforms 81.96% of its industry peers.
PCRX had an Average Return On Invested Capital over the past 3 years of 4.32%. This is significantly below the industry average of 17.97%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.46% | ||
| ROE | 7.91% | ||
| ROIC | 4.27% |
ROA(3y)1.88%
ROA(5y)3.15%
ROE(3y)4.21%
ROE(5y)6.6%
ROIC(3y)4.32%
ROIC(5y)4.07%
1.3 Margins
With an excellent Profit Margin value of 10.35%, PCRX belongs to the best of the industry, outperforming 87.11% of the companies in the same industry.
In the last couple of years the Profit Margin of PCRX has declined.
PCRX has a Operating Margin of 13.71%. This is amongst the best in the industry. PCRX outperforms 85.05% of its industry peers.
PCRX's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 73.16%, PCRX is in the better half of the industry, outperforming 78.87% of the companies in the same industry.
In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.71% | ||
| PM (TTM) | 10.35% | ||
| GM | 73.16% |
OM growth 3Y-2.79%
OM growth 5Y20.05%
PM growth 3Y-43.17%
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y-0.43%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PCRX is destroying value.
The number of shares outstanding for PCRX has been increased compared to 1 year ago.
PCRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PCRX has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.69, we must say that PCRX is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.69, PCRX is doing good in the industry, outperforming 63.40% of the companies in the same industry.
The Debt to FCF ratio of PCRX is 3.00, which is a good value as it means it would take PCRX, 3.00 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of PCRX (3.00) is better than 89.69% of its industry peers.
PCRX has a Debt/Equity ratio of 0.57. This is a neutral value indicating PCRX is somewhat dependend on debt financing.
PCRX's Debt to Equity ratio of 0.57 is on the low side compared to the rest of the industry. PCRX is outperformed by 62.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.57 | ||
| Debt/FCF | 3 | ||
| Altman-Z | 1.69 |
ROIC/WACC0.53
WACC8.1%
2.3 Liquidity
PCRX has a Current Ratio of 5.81. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.81, PCRX is in the better half of the industry, outperforming 68.04% of the companies in the same industry.
PCRX has a Quick Ratio of 4.78. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
PCRX's Quick ratio of 4.78 is in line compared to the rest of the industry. PCRX outperforms 59.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.81 | ||
| Quick Ratio | 4.78 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 21.37% over the past year.
PCRX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 22.93% yearly.
The Revenue has been growing slightly by 1.88% in the past year.
The Revenue has been growing by 14.88% on average over the past years. This is quite good.
EPS 1Y (TTM)21.37%
EPS 3Y9.9%
EPS 5Y22.93%
EPS Q2Q%16.98%
Revenue 1Y (TTM)1.88%
Revenue growth 3Y16.25%
Revenue growth 5Y14.88%
Sales Q2Q%4.23%
3.2 Future
Based on estimates for the next years, PCRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.29% on average per year.
PCRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.72% yearly.
EPS Next Y-3.12%
EPS Next 2Y11.9%
EPS Next 3Y14.62%
EPS Next 5Y15.29%
Revenue Next Year2.49%
Revenue Next 2Y5.99%
Revenue Next 3Y7.19%
Revenue Next 5Y8.72%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PCRX is valuated cheaply with a Price/Earnings ratio of 6.65.
95.36% of the companies in the same industry are more expensive than PCRX, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 24.29, PCRX is valued rather cheaply.
PCRX is valuated cheaply with a Price/Forward Earnings ratio of 5.48.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 95.36% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.35, PCRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.65 | ||
| Fwd PE | 5.48 |
4.2 Price Multiples
PCRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PCRX is cheaper than 94.85% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, PCRX is valued cheaper than 96.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.38 | ||
| EV/EBITDA | 5.85 |
4.3 Compensation for Growth
PCRX has a very decent profitability rating, which may justify a higher PE ratio.
PCRX's earnings are expected to grow with 14.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)0.29
EPS Next 2Y11.9%
EPS Next 3Y14.62%
5. Dividend
5.1 Amount
PCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PACIRA BIOSCIENCES INC
NASDAQ:PCRX (7/26/2024, 3:10:08 PM)
After market: 20.03 0 (0%)20.03
+0.05 (+0.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap932.40M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.65 | ||
| Fwd PE | 5.48 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)0.29
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.46% | ||
| ROE | 7.91% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 13.71% | ||
| PM (TTM) | 10.35% | ||
| GM | 73.16% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.57 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.81 | ||
| Quick Ratio | 4.78 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)21.37%
EPS 3Y9.9%
EPS 5Y
EPS Q2Q%
EPS Next Y-3.12%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1.88%
Revenue growth 3Y16.25%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y